In a prior meta-analysis, the use of angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) reduced the relative risk of AF by 28% (p=.00002) with significant reductions seen in heart failure and left ventricular hypertrophy [95]. This evidence concerns the gene ACE and atrial fibrillation.